







# The Pharmaceutical Market 2020

May 2021

# The Public Sector Remains a Major Growth Driver for the Pharmaceutical Market\*

Including dietary supplements, medical accessories and other products ~ RUB 2,126 bln and 9.9 bln packs




\*Medicines only  
According to AlphaRM analytics databases

■ Public Sector

■ Retail


# Structure of the Russian Pharmaceutical Market\*

By value, 2020 (RUB, sell out)



# Structure of the Russian Pharmaceutical Market\*

By volume, 2020 (packs, sell out)



**Including dietary supplements and miscellaneous other products** 9.9 BLN PACKS  $\Delta +9%$




# PHARMACY MARKET



# Russia's Retail Pharma Market in Consumer Prices, 2020 RUB ~1,501 billion\* & ~9.00 billion packs


Total Value, RUB bln



- Medicines (RX)  $\triangle +16\%$
- Medicines (OTC)  $\triangle +18\%$
- Other products  $\triangle +4\%$
- Dietary supplements  $\triangle +31\%$

## Sales dynamic of pharmacy products

Total Volume, bln packs





- Medicines (RX)  $\triangle +12\%$
- Medicines (OTC)  $\triangle +10\%$
- Other products  $\triangle +8\%$
- Dietary supplements  $\triangle +18\%$



\* including dietary supplements and miscellaneous other products  
According to AlphaRM analytics databases

$\triangle \nabla$  Increment 2020/2019, %

# There are more than 68,600 pharmacies in Russia at the end of M'12 2020



## POS growth leaders

**АПРЕЛЬ** (Krasnodar)


**ЭМПЛОЗИА** (Samara)

**РИГЛА** (Moscow)



\* including dietary supplements and miscellaneous other products  
According to AlphaRM analytics databases

## Growth dynamic in no. of pharmacies



## TOP 20 Pharmacy Chains in 2020

Ranking	Variation in ranking	Pharmacy chain	Growth in earnings 2020/2019 (%), RUB	No. of pharmacies as at 1 January 2021	Share, 2020, %
1	-	Rigla (Moscow)		3,173	5.8%
2	+1	Implozia (Samara)		3,204	5.0%
3	-1	Erka Pharm Group		1,062	4.5%
4	-	Planeta Zdorovya (Perm)		1,859	3.8%
5	+3	Aprel (Krasnodar)		1,892	3.5%
6	-	Neopharm (Moscow)		820	3.4%
7	-2	GROUP 36.6 (MOSCOW)		1,496	3.2%
8	-1	Vita (Samara)		1,819	3.1%
9	-	Pharmland (Ufa)		1,321	2.4%
10	-	Melodiya Zdorovya (Novosibirsk)		860	1.6%
11	+3	36.7C&Maksavit (Nizhny Novgorod)		644	1.4%
12	+1	Pharmaimpex (Izhevsk)		668	1.4%
13	-1	Apteka ot sklada (Perm)		866	1.3%
14	+5	ZDOROV.ru (Moscow)		96	1.1%
15	*	Pharmakopeika (Omsk)		606	0.9%
16	-1	Pharmatsevt+ (Rostov-on-Don)		510	0.9%
17	+3	Gubernskiye apteki (Krasnoyarsk)		309	0.8%
18	-	Nevis (St. Petersburg)		555	0.8%
19	+7	Magnit (Krasnodar)		1,164	0.8%
20	-4	Novaya apteka & Apteka Minitsen...		174	0.8%

46%

The TOP 20 pharmacy chains consolidated 45.1% of the retail market in 2019



\*the Pharmakopeika & Tvoi Doktor chain split up in January 2020  
According to AlphaRM analytics databases



## Regions where the Leaders' Market Share Exceeds 20%, 2020

Pharmacy chain's share in the region

- above 20%
- 15% to 20%
- 10% to 15%
- below 10%

**52/46** regions

**39/33** pharmacy chains



According to AlphaRM analytics databases

### TOP 10

61% – the chain's market share in the region, RUB (%)  
 646 – no. of POS operated by the pharmacy chain with a market share of over 20% in the region


# Average Monthly Earnings per Pharmacy by Region, 2020

Federal District	Average monthly earnings per pharmacy, RUB '000	Increment average monthly earnings per pharmacy	Average check
Northwestern Federal District	2,486	13%	543
Central Federal District	2,050	12%	497
Far Eastern Federal District	1,877	12%	532
Siberian Federal District	1,752	16%	486
Ural Federal District	1,734	8%	467
Southern Federal District	1,661	10%	417
Volga Federal District	1,629	14%	462
North Caucasian Federal District	1,168	11%	388

## Russian Federation

Average monthly earnings per pharmacy:  
 ~ **RUB 1,841,000** △ +12%

TOP 5 regions with threshold performance



According to AlphaRM analytics databases

RUB '000

# Concentration of Pharmacies by Region, M'12 2020


Federal District	No. of pharmacies	Increment 2020/2019	No. of POS per 10,000 people
Central Federal District	19,382	0%	4.9
Volga Federal District	13,837	1%	4.7
Southern Federal District	8,640	5%	5.2
Siberian Federal District	7,997	2%	4.7
Northwestern Federal District	6,233	5%	4.5
Ural Federal District	5,711	0%	4.6
North Caucasian Federal District	3,473	8%	3.5
Far Eastern Federal District	3,339	2%	4.1

## Russian Federation

No. of pharmacies: **68,600** ▲+2%

No. of POS per 10,000 people: **4.7**

TOP 5 regions with threshold performance




According to AlphaRM analytics databases

per 10,000 people

# Weekly Dynamic of Medicine Sales by Pharmacies, 2019-W'16 2021

2020/2019  $\triangle +17\%$   
 W'1-W'16 21/  
 W'1-W'16 20  $\triangle +5\%$


RUB bln



---- USD exchange rate, 2020

2020/2019  $\triangle +10\%$   
 W'1-W'16 21/  
 W'1-W'16 20  $\nabla -12\%$

Mln packs



— 2019 — 2020 — 2021



Week 1 of 2020 includes data from 30 December 2019 to 5 January 2020  
 Week 53 of 2020 includes data from 28 December 2020 to 3 January 2021  
 Week 1 of 2021 includes data from 4 to 10 January 2021

Medicines only  
 Extrapolated data


According to the DB 'Retail monitoring of pharmacy sales of drugs and dietary supplements in the Russian Federation'

**Pharmacy sales peaked during week 12 in 2020**




# Contributors to Medicine Sales Growth by Pharmacies by Value, 2020

	USD		EUR	
2020	RUB 71.94	↑	RUB 82.84	↑
2019	RUB 64.73	+11%	RUB 72.49	+14%




## 21,000 sku's of medicines on retail market

### New products 972 sku's



### Gone from market 1,390 sku's




### Top 3 EphMRA

EphMRA (level 2)	No. of sku's
<b>J1</b> systemic antibacterial medicines	89
<b>M1</b> inflammation suppressants and antirheumatics	84
<b>V3</b> other therapeutic products	69

### Top 3 EphMRA

EphMRA (level 2)	No. of sku's
<b>J1</b> systemic antibacterial medicines	129
<b>K1</b> intravenous preparations	101
<b>L1</b> antitumorals	85

# Pharmacy Sales of Medicines by Company Category and whether Sold OTC/RX by Value, 2020



## TOP 3 Category Leaders, 2020


Category	Corporation	Share RUB	Increment 20/19
Multi national	BAYER	7,9%	+22%
	NOVARTIS	7,3%	+23%
	STADA	6,3%	+6%
Foreign	Reckitt Benckiser	8,8%	+7%
	Bionorica	7,3%	+4%
	BAUSCH+Health	7,2%	+11%
Russian	otc Pharm	10,5%	+50%
	VALENTA	5,2%	+69%
	OZON	4,9%	+51%



Multinational: pharmaceuticals manufactured in Russia and elsewhere.  
 Russian companies: over 20% of sales in RUB accounted for by medicines produced domestically.  
 According to AlphaRM analytics databases



# Pharmacy Sales of Medicines by Company Category and whether Name-brand/Generic, 2020

Russian name-brand medicines saw the steepest sales growth





The rest are the long-familiar combinations of active ingredients and medicines of animal or herbal extraction  
According to AlphaRM analytics databases

# Structure and Dynamic of Pharmacy Sales of Medicines by Price Bracket, 2020



Medicine sales dynamic by price bracket\*, 2020



\*Excluding SKUs that move between price brackets during the year



# Private Spending on Medicine Purchases, 2020

Federal District	Spending per 1 person, RUB	FD share, RUB (%)	Increment, RUB 2020/2019
Central Federal District	9,135	31%	14%
Volga Federal District	7,188	18%	18%
Northwestern Federal District	10,037	12%	20%
Southern Federal District	7,918	11%	21%
Siberian Federal District	7,418	11%	20%
Ural Federal District	7,500	8%	12%
Far Eastern Federal District	6,812	5%	15%
North Caucasian Federal District	3,473	3%	22%


## Russian Federation

RUB 7,845 per person ▲ +17%

Region's market share 2020, RUB (%)

- >5%
- 3%–5%
- 1.5%–3%
- 0.5%–1.5%
- <0.5%

TOP 10 regions with threshold performance



11.7% – Region's share, RUB (%)  
 14,574 – Spending per 1 person, RUB  
 +62% – Increment 2020/2019, (%)




According to AlphaRM analytics databases


# Key Indicators of the Retail Market Product Range

Share by value (RUB, sell out)


## Name-brand/Generic




## Prescription/Non-prescription medicines, 2020



## Localisation of production



## VED/non-VED, 2020




\*Medicines only  
According to AlphaRM analytics databases


# Key Indicators of the Retail Market Product Range

## Share by volume (packs, sell out)


### Name-brand/Generic




### Prescription/Non-prescription medicines, 2020



### Localisation of production



### VED/non-VED, 2020








*\*Medicines only  
According to AlphaRM analytics databases*

## Leading EphMRA Groups (Level 2) in the Retail Market by Value\*, 2020

Ranking	Variation in ranking	EphMRA group (level 2)	Share, RUB (%) 2020	Increment 2020/2019, RUB (%)	Median price, RUB
1	-	<b>C9</b> ACE inhibitors	5,13%	18%	251
2	+13	<b>J5</b> antivirals for systemic use	4,73%	113%	464
3	-1	<b>R5</b> cough and cold medicines	4,46%	11%	176
4	+5	<b>J1</b> systemic antibacterial medicines	4,18%	53%	159
5	+1	<b>B1</b> anti-coagulants	4,12%	38%	631
6	-2	<b>M1</b> inflammation suppressants and antirheumatics	3,82%	14%	193
7	-4	<b>R1</b> nasal preparations	3,66%	6%	128
8	-3	<b>G3</b> reproductive hormones and products with similar effects (systemic action)	3,35%	6%	965
9	-2	<b>N6</b> psychoactivators, excluding anti-obesity drugs	3,02%	5%	320
10	-2	<b>G4</b> urological medicines	2,88%	4%	607



## Leading EphMRA Groups (Level 2) in the Retail Market by Value Growth, 2020


Ranking		Increment 2020/2019, RUB (%)	Median price, RUB (%)	Leading brand	
1	J5 antivirals for systemic use	4,7%	113%	464	
2	L3 immunostimulants	2,8%	58%	474	
3	J1 systemic antibacterial medicines	4,2%	53%	159	
4	B1 anti-coagulants	4,1%	38%	631	
5	D8 antiseptics and disinfectants	1,5%	30%	50	

# Group Analysis of Antiviral Medicines for Systemic Use\*, 2019-W'16 2021

Rub bln




Median price, RUB



## Dynamics of TOP 3 leading brands in group

RUB mln



— Ingavirin



24,6%

— Arbidol



21,0%

— Kagocel



8,2%

Brands' shares in group, 2020



Week 1 of 2020 includes data from 30 December 2019 to 5 January 2020


Week 53 of 2020 includes data from 28 December 2020 to 3 January 2021

Week 1 of 2021 includes data from 4 to 10 January 2021


\*EphMRA group (level 2) J5

According to AlphaRM analytics databases

# Analysis of Vitamin D Group Medicines\*, 2019-W'16 2021



## Dynamics of TOP 3 leading brands in group



73,1%



10,8%



10,1%

Brands' shares in group, 2020



Week 1 of 2020 includes data from 30 December 2019 to 5 January 2020

Week 53 of 2020 includes data from 28 December 2020 to 3 January 2021


Week 1 of 2021 includes data from 4 to 10 January 2021

\*EphMRA group (level 4) A11C2


According to AlphaRM analytics databases

# Analysis of the Antidepressants and Mood Medication Group\* by Value, 2019-W'16 2021


RUB mln  
 2020/2019  $\triangle +23\%$   
 W'1-W'16 21/W'1-W'16 20  $\triangle +10\%$



## Median price, RUB



## Dynamics of TOP 3 leading brands in group



— Zoloft



11,3%

— Cipraleks



11,2%

— Fevarin



9,4%


Brands' shares in group, 2020



Week 1 of 2020 includes data from 30 December 2019 to 5 January 2020  
 Week 53 of 2020 includes data from 28 December 2020 to 3 January 2021  
 Week 1 of 2021 includes data from 4 to 10 January 2021

\*EphMRA group (level 3) N6A  
 According to AlphaRM analytics databases

## Corporations Leading the Retail Market by Value (sell out)\*, 2020



# Leading Retail Brands by Value\*, 2020


OTC medicines						RX medicines					
Ranking	Variation in ranking	Brand of medicine	Share, RUB (%) 2020	Increment 2020/2019, RUB (%)	Increment 2020/2019, RUB (%)	Ranking	Variation in ranking	Brand of medicine	Share, RUB (%) 2020	Increment 2020/2019, RUB (%)	Increment 2020/2019, RUB (%)
1	+6	Ingavirin	2,37%	167%	105%	1	-	Xarelto	2,41%	46%	40%
2	+37	Arbidol	2,02%	405%	299%	2	+3	Eliquis	1,51%	95%	92%
3	-1	Detralex	1,29%	9%	3%	3	-1	Mexidol	1,13%	2%	0%
4	-3	Nurofen	1,27%	5%	8%	4	-1	Concor	1,06%	8%	8%
5	-2	Miramistin	1,18%	17%	6%	5	-1	Aktovegin	0,88%	-9%	-20%
6	-2	Pentalgin	1,10%	18%	6%	6	+1	Lorista	0,85%	17%	9%
7	+1	Theraflu	1,07%	21%	11%	7	+8	Amoxiclav	0,84%	45%	35%
8	-3	Cardiomagnyl	1,02%	12%	6%	8	-2	Lozap	0,80%	4%	-6%
9	+8	ACC	0,85%	61%	38%	9	+92	Azithromycin	0,79%	299%	215%
10	-	Linex	0,85%	29%	10%	10	-2	Nimesil	0,75%	15%	19%



\*Medicines only  
According to AlphaRM analytics databases





# Retail Market Growth Leaders\*, 2020/2019




# Market for Online Pharma Sales, 2020

68,6 00 pharmacies in total

**29,400 pharmacies** take online orders



## Ranking of on-line sales platforms, 2020



Other leading pharmacy chains by online sales



АПТЕКА ОТ СКЛАДА





## On-line and Off-line Retail Sales, 2020

On-line

**RUB 395**

Off-line

**RUB 167**

Median price  
All offerings

**RUB 1,551**


**RUB 472**

Average check

# PUBLIC SECTOR




# Public Procurement Market Stage-by-Stage\*, 2020



\*Procurement outside investment projects  
According to AlphaRM analytics databases


▲ ▼ Increment 2020/2019, %

# Structure of the Public Sector of the Russian Pharmaceutical Market\*, 2020





## Leading Corporations in the Public Procurement Sector by Value (sell out)\*, 2020



# Public Spending on Medicine Procurement, 2020

Federal District	Spending per 1 person, RUB	FD share, RUB (%)	Increment, RUB 2020/2019, (%)
Central Federal District	5,156	33%	16%
Volga Federal District	3,503	16%	39%
Siberian Federal District	4,189	11%	31%
Northwestern Federal District	4,878	11%	29%
Ural Federal District	4,660	9%	36%
Southern Federal District	3,396	9%	31%
Far Eastern Federal District	4,659	6%	32%
North Caucasian Federal District	2,778	4%	36%


## Russian Federation

RUB 4,259 per person ▲ +27%

Region's market share 2020, RUB (%)


- >5%
- 3%–5%
- 1.5%–3%
- 0.5%–1.5%
- <0.5%

TOP 5 regions with threshold performance




According to AlphaRM analytics databases

# Key Factors to Impact the Market in 2021



## Pharmaceutical Market Forecast through 2021\*



■ Retail ■ Public Sector

*\*Medicines only  
According to AlphaRM analytics databases*



**Thank you for your attention!**

Moscow, Obrucheva, 30/1 p. 2

[www.alpharm.ru](http://www.alpharm.ru)

